292 related articles for article (PubMed ID: 11840256)
1. Thalidomide for the treatment of patients with myelodysplastic syndromes.
Strupp C; Germing U; Aivado M; Misgeld E; Haas R; Gattermann N
Leukemia; 2002 Jan; 16(1):1-6. PubMed ID: 11840256
[TBL] [Abstract][Full Text] [Related]
2. Combination of 5-azacytidine and thalidomide for the treatment of myelodysplastic syndromes and acute myeloid leukemia.
Raza A; Mehdi M; Mumtaz M; Ali F; Lascher S; Galili N
Cancer; 2008 Oct; 113(7):1596-604. PubMed ID: 18720364
[TBL] [Abstract][Full Text] [Related]
3. Cyclosporin A therapy for patients with myelodysplastic syndrome: multicenter pilot studies in Japan.
Shimamoto T; Tohyama K; Okamoto T; Uchiyama T; Mori H; Tomonaga M; Asano Y; Niho Y; Teramura M; Mizoguchi H; Omine M; Ohyashiki K
Leuk Res; 2003 Sep; 27(9):783-8. PubMed ID: 12804635
[TBL] [Abstract][Full Text] [Related]
4. Refractory cytopenia with multilineage dysplasia: further characterization of an 'unclassifiable' myelodysplastic syndrome.
Rosati S; Mick R; Xu F; Stonys E; Le Beau MM; Larson R; Vardiman JW
Leukemia; 1996 Jan; 10(1):20-6. PubMed ID: 8558932
[TBL] [Abstract][Full Text] [Related]
5. Cyclosporin A and thalidomide in patients with myelodysplastic syndromes: Results of a pilot study.
Xiao Z; Xu Z; Zhang Y; Qin T; Zhang H; Fang L
Leuk Res; 2011 Jan; 35(1):61-5. PubMed ID: 20591481
[TBL] [Abstract][Full Text] [Related]
6. Cyclosporin A in myelodysplastic syndrome: a preliminary report.
Dixit A; Chatterjee T; Mishra P; Choudhary DR; Mahapatra M; Saxena R; Choudhry VP
Ann Hematol; 2005 Sep; 84(9):565-8. PubMed ID: 15809884
[TBL] [Abstract][Full Text] [Related]
7. [Cyclosporine A based therapy for myelodysplastic syndrome].
Li ZL; Gong M; Xu SH; Huang FZ; Chen YR; Ma YG
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2005 Oct; 13(5):867-70. PubMed ID: 16277860
[TBL] [Abstract][Full Text] [Related]
8. Cytogenetic evolution following the transformation of myelodysplastic syndrome to acute myelogenous leukemia: implications on the overlap between the two diseases.
Ghaddar HM; Stass SA; Pierce S; Estey EH
Leukemia; 1994 Oct; 8(10):1649-53. PubMed ID: 7934160
[TBL] [Abstract][Full Text] [Related]
9. [Retrospective analysis of hemotherapy support in 226 cases of myelodysplastic syndromes].
Rubio-Félix D; Franco E; Giraldo P; Gimeno J; Cuesta I; Giralt M
Sangre (Barc); 1994 Apr; 39(2):117-20. PubMed ID: 8059289
[TBL] [Abstract][Full Text] [Related]
10. Investigation for the presence of anti-erythropoietin antibodies in patients with myelodysplastic syndromes.
Voulgari PV; Hatzimichael EC; Tsiara S; Tzallas C; Drosos AA; Bourantas KL
Eur J Haematol; 2001 Jan; 66(1):31-6. PubMed ID: 11168505
[TBL] [Abstract][Full Text] [Related]
11. [Long-term effects of androgen combined with low dose all-trans-retinoic acid on myelodysplastic syndrome: follow-up of 60 cases].
Guan M; Chen SC; Ge CW
Zhonghua Yi Xue Za Zhi; 2009 Apr; 89(13):919-22. PubMed ID: 19671296
[TBL] [Abstract][Full Text] [Related]
12. Treatment of patients with low-risk myelodysplastic syndromes using a combination of all-trans retinoic acid, interferon alpha, and granulocyte colony-stimulating factor.
Hofmann WK; Ganser A; Seipelt G; Ottmann OG; Zander C; Geissler G; Hoffmann K; Höffken K; Fischer JT; Isele G; Hoelzer D
Ann Hematol; 1999 Mar; 78(3):125-30. PubMed ID: 10211754
[TBL] [Abstract][Full Text] [Related]
13. Busulfan, cyclophosphamide and melphalan as conditioning regimen for bone marrow transplantation in children with myelodysplastic syndromes.
Locatelli F; Pession A; Bonetti F; Maserati E; Prete L; Pedrazzoli P; Zecca M; Prete A; Paolucci P; Cazzola M
Leukemia; 1994 May; 8(5):844-9. PubMed ID: 8182940
[TBL] [Abstract][Full Text] [Related]
14. Role of splenectomy in the treatment of myelodysplastic syndromes with peripheral thrombocytopenia: a report on six cases.
Bourgeois E; Caulier MT; Rose C; Dupriez B; Bauters F; Fenaux P
Leukemia; 2001 Jun; 15(6):950-3. PubMed ID: 11417482
[TBL] [Abstract][Full Text] [Related]
15. Successful treatment of refractory anemia with a combination regimen containing recombinant human erythropoietin, low-dose methylprednisolone and nandrolone.
Tsiara SN; Chaidos A; Gouva M; Christou L; Panteli K; Kapsali E; Bourantas KL
J Exp Clin Cancer Res; 2004 Mar; 23(1):47-52. PubMed ID: 15149150
[TBL] [Abstract][Full Text] [Related]
16. [Analysis of 4 prognostic scoring systems in 197 myelodysplastic syndrome patients].
Rubio-Félix D; Giraldo MP; Perella M; Gimeno J; Franco E; Giralt M
Sangre (Barc); 1991 Dec; 36(6):463-9. PubMed ID: 1812580
[TBL] [Abstract][Full Text] [Related]
17. Cytogenetic studies in 32 patients with myelodysplastic syndrome: insights to specific chromosomal abnormalities and prognosis.
Taniwaki M; Horiike S; Inazawa J; Nishida K; Misawa S; Takino T; Abe T
Jpn J Clin Oncol; 1987 Jun; 17(2):141-50. PubMed ID: 3613138
[TBL] [Abstract][Full Text] [Related]
18. Antithymocyte globulin (ATG)-based therapy in patients with myelodysplastic syndromes.
Yazji S; Giles FJ; Tsimberidou AM; Estey EH; Kantarjian HM; O'Brien SA; Kurzrock R
Leukemia; 2003 Nov; 17(11):2101-6. PubMed ID: 12931212
[TBL] [Abstract][Full Text] [Related]
19. [Chromosome abnormalities in myelodysplastic syndrome].
Fujita K; Mori H; Niikura H; Terada H; Shinohara T
Rinsho Byori; 1990 Aug; 38(8):911-6. PubMed ID: 2232253
[TBL] [Abstract][Full Text] [Related]
20. A non-randomised dose-escalating phase II study of thalidomide for the treatment of patients with low-risk myelodysplastic syndromes: the Thal-SMD-2000 trial of the Groupe Français des Myélodysplasies.
Bouscary D; Legros L; Tulliez M; Dubois S; Mahe B; Beyne-Rauzy O; Quarre MC; Vassilief D; Varet B; Aouba A; Gardembas M; Giraudier S; Guerci A; Rousselot P; Gaillard F; Moreau A; Rousselet MC; Ifrah N; Fenaux P; Dreyfus F;
Br J Haematol; 2005 Dec; 131(5):609-18. PubMed ID: 16351636
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
